Clinical Trial Update: Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of bortezomib (Velcade) in Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Status: COMPLETED